Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study.

Komuta K, Matsumoto K, Tamiya M, Shiroyama T, Kinehara Y, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nishino K, Takeda Y, Kumanogoh A

Open source

DOI
10.1016/j.jtocrr.2026.101048
Published
2026 Sep
Container
JTO clinical and research reports
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2026.101048,
  title = {Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study.},
  author = {Komuta K and Matsumoto K and Tamiya M and Shiroyama T and Kinehara Y and Tamiya A and Kuge T and Uchida J and Suzuki H and Yamamoto S and Tobita S and Niki T and Tetsumoto S and Morimura O and Osa A and Minami T and Nishino K and Takeda Y and Kumanogoh A},
  year = {2026},
  journal = {JTO clinical and research reports},
  doi = {10.1016/j.jtocrr.2026.101048},
  url = {https://doi.org/10.1016/j.jtocrr.2026.101048}
}

RIS

TY  - JOUR
TI  - Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study.
AU  - Komuta K
AU  - Matsumoto K
AU  - Tamiya M
AU  - Shiroyama T
AU  - Kinehara Y
AU  - Tamiya A
AU  - Kuge T
AU  - Uchida J
AU  - Suzuki H
AU  - Yamamoto S
AU  - Tobita S
AU  - Niki T
AU  - Tetsumoto S
AU  - Morimura O
AU  - Osa A
AU  - Minami T
AU  - Nishino K
AU  - Takeda Y
AU  - Kumanogoh A
PY  - 2026
JO  - JTO clinical and research reports
DO  - 10.1016/j.jtocrr.2026.101048
UR  - https://doi.org/10.1016/j.jtocrr.2026.101048
ER  - 

APA

K, K., K, M., M, T., T, S., Y, K., A, T., T, K., J, U., H, S., S, Y., S, T., T, N., S, T., O, M., A, O., T, M., K, N., Y, T., & A, K. (2026). Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2026.101048

Source records